The Aastrom experience

Aastrom Biosciences has developed a proprietary cell-processing technology that enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a small sample of a patient's own bone marrow. Ixmyelocel-T is produced under current good manufacturing practices (cGM...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartel, Ronnda L, Cramer, Caryn, Ledford, Kelly, Longcore, Amy, Parrish, Christopher, Stern, Theresa, Watling, Sharon, Zeigler, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580464/
https://www.ncbi.nlm.nih.gov/pubmed/22776246
http://dx.doi.org/10.1186/scrt117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580464/
https://www.ncbi.nlm.nih.gov/pubmed/22776246
http://dx.doi.org/10.1186/scrt117

Ejemplares similares